Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication
DREAM trial washout results
In Diabetes Care, we describe how withdrawing rosiglitazone and ramipril medication affects diabetes incidence after the closeout of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
A set of 3,366 subjects who had not developed diabetes by the end of the trial, but who had been taking double-blinded medication, were transferred to single-blinded placebo for 2 to 3 months, and their glycaemic statuses analysed....
DREAM drug washout study results
DREAM drug washout study results released at IDF WDC2006 Cape Town
Download DREAM trial results slides
DREAM trial results